ArticleCells2021
Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model.
Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Data-driven modeling of spatiotemporal dynamics using multimodal imaging data.PLoS computational biology · 2026Article
- Next-generation osteosarcoma models for precision medicine.Communications biology · 2026Review
- Predicting head and neck cancer response to radiotherapy using mathematical modeling of MRI-based habitats.NPJ precision oncology · 2026Article
- Article
- Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials.Biomedicines · 2025Review
- Oxygen, angiogenesis, cancer and immune interplay in breast tumour microenvironment: a computational investigation.Royal Society open science · 2024Article
- Optimal fusion of genotype and drug embeddings in predicting cancer drug response.Briefings in bioinformatics · 2024Article
- Digital twins for health: a scoping review.NPJ digital medicine · 2024Article
- Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Article
- Article
- Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment.Journal of personalized medicine · 2022Article
- A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice.Journal of personalized medicine · 2022Article
- Investigating key cell types and molecules dynamics in PyMT mice model of breast cancer through a mathematical model.PLoS computational biology · 2022Article
- Novel Immunotherapies for Osteosarcoma.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Since all tumors are unique, they may respond differently to the same treatments. Therefore, it is necessary to study their characteristics individually to find their best treatment options. We built a mathematical model for the interactions between the most common chemotherapy drugs and the osteosarcoma microenvironments of three clusters of tumors with unique immune profiles. We then investigated the effects of chemotherapy with different treatment regimens and various treatment start times on the behaviors of immune and cancer cells in each cluster. Saliently, we suggest the optimal drug dosages for the tumors in each cluster. The results show that abundances of dendritic cells and HMGB1 increase when drugs are given and decrease when drugs are absent. Populations of helper T cells, cytotoxic cells, and IFN-γ grow, and populations of cancer cells and other immune cells shrink during treatment. According to the model, the MAP regimen does a good job at killing cancer, and is more effective than doxorubicin and cisplatin combined or methotrexate alone. The results also indicate that it is important to consider the tumor's unique growth rate when deciding the treatment details, as fast growing tumors need early treatment start times and high dosages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.